Dapagliflozin for early Alport kidney disease in teens and young adults
Treatments studied
Part of Genetic & congenital, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests dapagliflozin, a daily medicine, to slow kidney problems in people with early-stage chronic kidney disease caused by Alport syndrome. It may help protect kidney function and reduce worsening over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Alport syndrome confirmed by genetic testing or a kidney biopsy
- Your kidney disease is in an early stage: certain urine protein and kidney filtering levels must be met
- If you take blood pressure medicines that block the RAS system, your dose must be stable
- You are between age 10 and under 40, based on the trial’s specific urine protein and kidney function thresholds
- You have not taken an SGLT2 inhibitor (like dapagliflozin-class meds) in the last 4 weeks
- Your blood pressure is controlled (not above 145/95)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking dapagliflozin (a drug often used for diabetes and heart health) can help improve kidney structure and blood flow in people who received a kidney transplant at least 9 months ago. It may benefit those whose kidney function is stable, regardless of whether they have diabetes.
This trial tests whether a type of medicine called SGLT2 inhibitors can help teenagers with early-stage chronic kidney disease. It looks at how safe and effective these drugs are for slowing down kidney damage.
This trial tests if dapagliflozin, a medication that lowers blood sugar and protects the kidneys, can reduce protein in the urine of children with inherited kidney disease. It may help preserve kidney function when added to standard blood pressure medication.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This trial tests whether a diabetes medicine called dapagliflozin can help protect kidney function in people with AL amyloidosis. You must live in Michigan and have stable or improving protein in your urine.
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
Hear when a new Chronic Kidney Failure in Children and Young Adults trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.